DR. ALEXANDER B. NICULESCU, M.D., PH.D.
Psychiatric at 10 St, Indianapolis, IN
License number
Indiana A72565
Category
Psychiatric
Type
Psychiatry
Address
Address
1481 WEST 10Th St, Indianapolis, IN 46202
Phone
(317) 988-5712
Personal information
See more information about ALEXANDER B. NICULESCU at radaris.comName
Address
Phone
6510 Spring Mill Rd, Indianapolis, IN 46260
6510 Spring Mill Rd, Indianapolis, IN 46260
Professional information
See more information about ALEXANDER B. NICULESCU at trustoria.com
Associate Professor At Iu School Of Medicine
Associate Professor At Iu School Of Medicine
Location:
Indianapolis, Indiana Area
Industry:
Mental Health Care
Assistant Professor At Iu
Assistant Professor At Iu
Position:
Assistant Professor at IU
Location:
Indianapolis, Indiana Area
Industry:
Mental Health Care
Work:
IU
-
Assistant Professor
Alexander Bogdan Niculescu, Indianapolis IN
Alexander Bogdan Niculescu, Indianapolis IN
Specialties:
Psychiatry
Work:
Indianapolis VA / Roudebush VAMC
1481 W 10Th St, Indianapolis, IN 46202
1481 W 10Th St, Indianapolis, IN 46202
Education:
Universitatea De Medicina Si Farmacie Carol Davila (1991)
Alexander Bogdan Niculescu, Indianapolis IN
Alexander Bogdan Niculescu, Indianapolis IN
Specialties:
Psychiatrist
Address:
1481 W 10Th St, Indianapolis, IN 46202
Blood Biomarkers For Mood Disorders
Blood Biomarkers For Mood Disorders
US Patent:
2010025, Oct 7, 2010
Filed:
Apr 2, 2008
Appl. No.:
12/594378
Inventors:
Alexander B. Niculescu - Indianapolis IN, US
John I. Nurnberger - Indianapolis IN, US
Daniel R. Salomon - San Diego CA, US
John I. Nurnberger - Indianapolis IN, US
Daniel R. Salomon - San Diego CA, US
Assignee:
THE SCRIPPS RESEARCH INSTITUTE - La Jolla CA
International Classification:
C40B 30/00, G01N 33/68, C12Q 1/48, C12Q 1/44, C12Q 1/42, C12Q 1/02, C12Q 1/68, G01N 33/53
US Classification:
506 7, 436 86, 436 87, 435 15, 435 19, 435 21, 435 29, 435 6, 435 792
Abstract:
A plurality of markers determine the diagnosis of a mood disorder based on their expression in a sample such as blood. Subsets of biomarkers predict the diagnosis of high or low mood disorders. The biomarkers are identified using a convergent functional genomics approach based on animal and human data. Methods and compositions for clinical diagnosis of mood disorders are provided.
Blood Biomarkers For Psychosis
Blood Biomarkers For Psychosis
US Patent:
2011009, Apr 28, 2011
Filed:
May 13, 2008
Appl. No.:
12/599763
Inventors:
Alexander B. Niculescu - Indianapolis IN, US
Daniel R. Salomon - San Diego CA, US
Daniel R. Salomon - San Diego CA, US
Assignee:
THE SCRIPPS RESEARCH INSTITUTE - La Jolla CA
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION - Indianapolis IN
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION - Indianapolis IN
International Classification:
C40B 30/04, C12Q 1/68, G01N 33/53, C40B 40/04, C40B 40/10
US Classification:
506 9, 435 6, 435 792, 506 15, 506 18
Abstract:
A plurality of biomarkers determine the diagnosis of psychosis based on the expression levels in a sample such as blood. Subsets of biomarkers predict the diagnosis of delusion or hallucination. The biomarkers are identified using a convergent functional genomics approach based on animal and human data. Methods and compositions for clinical diagnosis of psychosis are provided.
Candidate Genes And Blood Biomarkers For Bipolar Mood Disorder, Alcoholism And Stress Disorder
Candidate Genes And Blood Biomarkers For Bipolar Mood Disorder, Alcoholism And Stress Disorder
US Patent:
2011004, Feb 24, 2011
Filed:
Sep 25, 2008
Appl. No.:
12/681154
Inventors:
Alexander B. Niculescu - Indianapolis IN, US
International Classification:
C40B 30/04, C12Q 1/68, G01N 33/566, C40B 30/00, C40B 40/08
US Classification:
506 9, 435 6, 435 792, 506 7, 506 17, 435 721
Abstract:
Analysis of the gene expression changes identified a series of novel candidate genes and blood biomarkers for bipolar disorder, alcoholism and stress disorder. These are used for diagnosing the disorders, predicting and monitoring response to treatment. A novel treatment for these co-morbid disorders, DHA (Docosahexaenoic acid—an omega-3 fatty acid) was identified, using these genes and biomarkers, as well as the transgenic animal model.